DeLorean Artificial Intelligence, a pioneering AI technology development company based in Miami, FL, has recently concluded a successful Series A funding round, raising an impressive $7.55 million. This latest injection of capital brings the company’s total funding to approximately $11 million, marking a significant milestone in the company’s growth trajectory. The funding was led by Sopris Venture Capital, with notable participation from Pinta Capital Partners and James Chow.
The primary objective behind this funding round is to expedite the expansion and widespread adoption of DeLorean.AI’s groundbreaking Medical AI product, both domestically, in the USA, and internationally, in Europe, the Middle East, and Latin & South America. DeLorean.AI, under the visionary leadership of its CEO and Founder, Dr. MacLaughlin, specializes in constructing sentient and semi-sentient systems of intelligence that tackle intricate business and economic challenges on behalf of Fortune 500 companies.
One of the company’s flagship offerings is Medical AI, a sophisticated artificial intelligence solution that revolutionizes the field of healthcare by offering a predictive and proactive approach to treatment. By leveraging advanced algorithms, this product effectively generates mathematical profiles of patient journeys and treatment methodologies, empowering medical professionals to make informed decisions that enhance patient outcomes.
In addition to Medical AI, DeLorean AI boasts a range of patent-pending AI capabilities, including CPG Sales AI, Service Ticket Analysis (Ticket Analysis Prediction Engine AI – TAPE AI), and Customer Relations Management AI (CRM AI), among others. CRM AI, which was the company’s first patented product, has demonstrated exceptional performance by accurately predicting deal winnability and evaluating the financial impact on revenue generation and costs. Compatible with any CRM platform, CRM AI’s powerful data analysis capabilities have resulted in significant sales growth for clients.
With this recent funding success, DeLorean Artificial Intelligence is poised to solidify its position as an industry leader in the development and application of AI solutions across multiple sectors. Armed with a diverse range of innovative products and a mission to drive progress through intelligent technologies, DeLorean.AI is set to reshape the future of artificial intelligence.
Frequently Asked Questions (FAQ)
1. What is DeLorean.AI?
DeLorean.AI is an artificial intelligence technology development company based in Miami, FL. It specializes in creating sentient and semi-sentient systems of intelligence to solve complex business challenges for Fortune 500 companies.
2. How much funding did DeLorean.AI recently secure?
DeLorean.AI raised $7.55 million in its Series A funding round, bringing its total funding to approximately $11 million.
3. What is Medical AI?
Medical AI is DeLorean.AI’s flagship product, which utilizes artificial intelligence to offer a predictive and proactive approach to treatment. It creates mathematical profiles of patient journeys and treatment methodologies to assist medical professionals in making informed decisions.
4. What other AI capabilities does DeLorean.AI possess?
DeLorean.AI holds patent-pending rights to various proprietary AI capabilities, including CPG Sales AI, Service Ticket Analysis (TAPE AI), and Customer Relations Management AI (CRM AI), among others. These capabilities provide unique solutions to specific business challenges in different industries.
5. How has CRM AI benefited clients?
CRM AI, DeLorean.AI’s first patented product, has demonstrated remarkable outcomes by predicting deal winnability and evaluating the financial impact of deals on revenue generation and costs. It can analyze structured and unstructured data to guide effective decision-making, resulting in significant sales growth for clients.